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Abstract
The coronavirus nucleocapsid protein (N) controls viral genome packaging and contains numerous phos-
phorylation sites located within unstructured regions. Binding of phosphorylated SARS-CoV N to the host
14-3-3 protein in the cytoplasm was reported to regulate nucleocytoplasmic N shuttling. All seven isoforms
of the human 14-3-3 are abundantly present in tissues vulnerable to SARS-CoV-2, where N can constitute
up to ~1% of expressed proteins during infection. Although the association between 14-3-3 and SARS-
CoV-2 N proteins can represent one of the key host-pathogen interactions, its molecular mechanism
and the specific critical phosphosites are unknown. Here, we show that phosphorylated SARS-CoV-2 N
protein (pN) dimers, reconstituted via bacterial co-expression with protein kinase A, directly associate,
in a phosphorylation-dependent manner, with the dimeric 14-3-3 protein, but not with its monomeric
mutant. We demonstrate that pN is recognized by all seven human 14-3-3 isoforms with various efficien-
cies and deduce the apparent KD to selected isoforms, showing that these are in a low micromolar range.
Serial truncations pinpointed a critical phosphorylation site to Ser197, which is conserved among related
zoonotic coronaviruses and located within the functionally important, SR-rich region of N. The relatively
tight 14-3-3/pN association could regulate nucleocytoplasmic shuttling and other functions of N via occlu-
sion of the SR-rich region, and could also hijack cellular pathways by 14-3-3 sequestration. As such, the
assembly may represent a valuable target for therapeutic intervention.
 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CCBY license (http://creativecom-
mons.org/licenses/by/4.0/).
Introduction
The new coronavirus-induced disease,
COVID19, has caused a worldwide health crisis
with more than 90 million confirmed cases and 1.9
million deaths as of January 2021.1 The pathogen
responsible, Severe Acute Respiratory Syndrome
Coronavirus 2 (SARS-CoV-2), is highly similar to
the causative agent of the SARS outbreak in
2002–2003 (SARS-CoV) and, to a lesser extent,
to the Middle East Respiratory Syndrome Coron-
avirus (MERS-CoV).2,3 Each is vastly more patho-
genic and deadly than human coronaviruses
HCoV-OC43, HCoV-NL63, HCoV-229E, and
HCoV-HKU1 which cause seasonal respiratory dis-
eases.4 Like SARS-CoV and HCoV-NL63, SARS-
0022-2836/ 2021 The Author(s). Published by Elsevier Ltd.This is an open access article under the CC BY license (http://creativecommons.org/
licenses/by/4.0/). Journal of Molecular Biology (2021) 433, 166875
Fast Track
CoV-2 uses angiotensin-converting enzyme 2
(ACE2) as entry receptor.5 The ACE2 expression
roughly correlates with the evidenced SARS-CoV-
2 presence in different tissue types, which explains
the multi-organ character of the disease6 (Figure 1).
In contrast to multiple promising COVID19
vaccine clinical trials,7–9 treatment of the disease
is currently limited by the absence of approved effi-
cient drugs.10 The failure of several leading drug
candidates in 2020 warrants the search for novel
therapeutic targets including not only viral enzymes,
but also heterocomplexes involving viral and host
cell proteins. Unravelling mechanisms of interaction
between the host and pathogen proteins may pro-
vide the platform for such progress.
The positive-sense single-stranded RNA genome
of SARS-CoV-2 coronavirus encodes
approximately 30 proteins which enable cell
penetration, replication, viral gene transcription
and genome assembly amongst other functions.11
The 46-kDa SARS-CoV-2 Nucleocapsid (N) protein
is 89.1% identical to SARS-CoV N. Genomic analy-
sis of human coronaviruses indicated that N might
be the major factor conferring the enhanced
pathogenicity to SARS-CoV-2.4 N represents the
most abundant viral protein in the infected
cell,12–14 with each assembled virion containing
approximately one thousand molecules of N.15
Given that each infected cell can contain up to 105
virions (infectious, defective and incomplete
overall),14 the number of N molecules in an infected
cell can reach 108, accounting for ~1% of a total
number of cellular proteins (~1010).16
The N protein interacts with viral genomic RNA,
the membrane (M) protein and self-associates to
provide for the efficient virion assembly.17–19 It con-
sists of two structured domains and three regions
predicted to be disordered (Figure 2(A)), including
a functionally important central Ser/Arg-rich
region20–22 and a set of potential protein-binding
sites (Figure 2(B)). Such organization allows for a
vast conformational change, which in combination
Figure 1. 14-3-3 proteins are highly abundant in human tissues with SARS-CoV-2 presence. Correlation of ACE2
expression levels (*) and SARS-CoV-2 reported presence (**) in various tissues of COVID19 patients based on the
data from Trypsteen et al.,6 shown with abundances (indicated in ppm, part per million, i.e., one molecule of a given
protein per 1 million of all proteins from a given tissue) of the seven human 14-3-3 isoforms, extracted from the PAXdb
database.40 Tissues are shown in the order corresponding to the SARS-CoV-2 presence, starting, at the top, from the
highest virus presence.6 The shown relative scale of ACE2 expression is also taken from Trypsteen et al.6 The total
abundance of the seven human 14-3-3 isoforms in a given tissue and the average abundance of an isoform in 12
selected tissues are also indicated. The latter values were used for ordering the data for 14-3-3 isoforms, left to right,
from the highest average abundance (14-3-3f; 2423 ppm, or ~0.24%) to the lowest average abundance (14-3-3g;
575 ppm, or ~0.06%). Note that the average abundance of all seven 14-3-3 proteins in three tissues with the highest
SARS-CoV-2 presence (oral cavity, gastrointestinal tract, lungs) reaches 1.21% of all proteins.
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with positively charged surfaces,23 facilitates
nucleic acid binding.24 Indeed, crystal structures of
the N-terminal domain (NTD) reveal an RNA bind-
ing groove,25–27 while crystal structures of the C-
terminal domain (CTD) show a highly interlaced
dimer with additional nucleic acid binding capac-
ity.28,29 The N protein shows unusual properties in
the presence of RNA, displaying concentration-
dependent liquid–liquid phase separation22,23,30,31
that is pertinent to the viral genome packaging
mechanism.32,33 In human cells, the assembly of
condensates is down-regulated by phosphorylation
of the SR-rich region.30,34 SARS-CoV-2 N protein is
a major target of phosphorylation by host cell pro-
tein kinases, with 22 phosphosites identified
in vivo throughout the protein (Supplementary
K.V. Tugaeva, Dorothy E.D.P. Hawkins, Jake L.R. Smith, et al. Journal of Molecular Biology 433 (2021) 166875
3
table 1).13,35 Functions of N and viral replication can
be regulated by a complex, hierarchical phosphory-
lation of the SR-rich region of SARS-CoV-2 N by a
cascade of protein kinases.36 Nevertheless, the
potential functional role of N phosphorylation at
each specific site is not understood.
Using immunofluorescence, immunoprecipita-
tion, siRNA silencing and kinase inhibition, it has
been shown that SARS-CoV N protein shuttles
between the nucleus and the cytoplasm in COS-1
cells.37 This process is regulated by N protein phos-
phorylation by several protein kinases including
glycogen synthase kinase-3, protein kinase A,
casein kinase II and cyclin-dependent kinase.37–39
Consequently, phosphorylated N associates with
14-3-3 proteins in the cytoplasm.37 Notably, treat-
ment with a kinase inhibitor cocktail eliminated the
N/14-3-3 interaction, whereas inhibition of 14-3-3h
expression by siRNA led to accumulation of N pro-
tein in the nucleus.37 These data suggest that 14-
3-3 proteins directly shuttle SARS-CoV N protein
in a phosphorylation-dependent manner: a role
which may be universal for N proteins of all coron-
aviruses, including SARS-CoV-2. However, the
molecular mechanism of the 14-3-3/N interaction
remains ill-defined.
14-3-3 proteins are amongst the top 1% of
highest-expressed human proteins in many
tissues, with particular abundance in tissues
vulnerable to SARS-CoV-2 infection including the
lungs, gastrointestinal system and brain40,41 (Fig-
ure 1). 14-3-3 proteins recognize hundreds of phos-
phorylated partner proteins involved in a magnitude
of cellular processes ranging from apoptosis to
cytoskeleton rearrangements.42,43 Human 14-3-3
proteins are present in most of the tissues as seven
conserved “isoforms” (b, c, e, f, g, r, s/h) (Figure 1),
with all-helical topology, forming dimers possessing
two identical antiparallel phosphopeptide-binding
grooves, located at ~35 A distance from each
other.44 By recognizing phosphorylated Ser/Thr
residues within the structurally flexible (R/K)X2-
3(pS/pT)X(P/G) consensus motif,
44,45 14-3-3 bind-
ing is known to regulate the stability of partner pro-
teins, their intracellular localization and interaction
with other factors.46 In addition to their high abun-
dance in many tissues susceptible to SARS-CoV-
2 infection (Figure 1) and a detectable increase of
expression of some 14-3-3 isoforms upon SARS-
CoV-2 infection,12 14-3-3 proteins were reported
as one of nine key host proteins during SARS-
CoV-2 infection.47 These data indicate a potential
association of 14-3-3 with viral proteins.
In this work, we dissected the molecular
mechanism of the interaction between SARS-
CoV-2 N and human 14-3-3 proteins. SARS-CoV-
2 N protein containing several phosphosites
reported to occur during infection, was produced
using the efficient Escherichia coli system that
proved successful for the study of
polyphosphorylated proteins.48 We have observed
the direct phosphorylation-dependent association
between polyphosphorylated SARS-CoV-2 N and
all seven human 14-3-3 isoforms and determined
the affinity and stoichiometry of the interaction. Ser-
ies of truncatedmutants of N localized the key 14-3-
3-binding site to a single phosphopeptide residing in
the functionally important SR-rich region of N.
These findings suggest a topology model for the
heterotetrameric 14-3-3/pN assembly occluding
3
Figure 2. Characterization of the SARS-CoV-2 N phosphoprotein. A. Prediction of the propensity to intrinsic
disorder (ID) and protein-binding regions across the SARS-CoV-2 N sequence made by DISOPRED 3.87 Scores
higher than 0.5 designate disorder. Protein-binding regions predicted by DISOPRED 387 are shown at scores higher
than 0.9. Two structured protein domains are also shown. B. Schematic representation of the N sequence and its
main features. The subdomains are named above (grey font), predicted Nuclear Export Signal (NES, yellow), Nuclear
Localization Signal (NLS, violet), N- and C-terminal domains (NTD, CTD) and two main phosphorylation loci (cyan
rectangles) are marked. Sequences of the SR-rich region and short phosphorylatable section of the CTD are shown
aligned between SARS-CoV and SARS-CoV-2 N proteins, highlighting multiple conserved phosphorylation sites (bold
font indicates phosphosites present in both N proteins and experimentally confirmed for SARS-CoV-2 N). Some
phosphosites (red spheres and labeled) are predicted as suboptimal 14-3-3-binding sites (green arrows). C. A Phos-
tag gel showing that bacterial co-expression of the full-length N with PKA yields polyphosphorylated protein. D. A
fragmentation spectrum of the representative phosphopeptide carrying phosphorylation at Ser197 and Thr205. Z-
(red) and c-series (blue) of ETD fragmentation are shown. Error did not exceed 5 ppm. E. Absorbance spectra show
that both recombinant unphosphorylated and PKA-phosphorylated N proteins elute from the Ni-affinity column bound
to random E. coli nucleic acid. On-column washing with 3 M NaCl (50 column volumes) eliminates bound nucleic acid.
F. Analysis of the oligomeric state of pN using size-exclusion chromatography (SEC) on a Superdex 200 Increase 10/
300 column at 200 mM NaCl, with multi-angle light scattering detection (SEC-MALS) and SDS-PAGE of the eluted
fractions. Flow rate was 0.8 ml/min. Apparent Mw determined from column calibration based on protein standards
(arrows above) is compared to the absolute mass determined from SEC-MALS. The experiments were carried out
three times, and the most typical results are shown.
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the SR-region, which presents a feasible target for
further characterization and therapeutic
intervention.
Results
Characterization of the polyphosphorylated N
protein obtained by co-expression with PKA in
E. coli
Host-expressed SARS-CoV-2 N protein
represents a phosphoprotein, harboring multiple
phosphorylation sites scattered throughout its
sequence. The most densely phosphorylated
locus is the SR-rich region (Figure 2(B),
Supplementary table 1, Supplementary data file
1).13,35 Remarkably, this region is conserved in N
proteins of several coronaviruses,39,49 including
SARS-CoV (Figure 2(B)). Although a number of
protein kinases have been implicated in SARS-
CoV N phosphorylation,36,37,39,50 the precise
enzymes responsible for identified phosphosites
and the functional outcomes are largely unknown.
Of note, many of the reported phosphosites within
the SARS-CoV-2 N protein are predicted to be
phosphorylated by protein kinase A (PKA) (Supple-
mentary table 1). Hence, PKA was used for produc-
tion of phosphorylated SARS-CoV-2 N in E. coli,48
using the same approach that was successfully
applied for production of several phosphorylated
eukaryotic proteins48,51–54 including the polyphos-
phorylated human tau competent for specific 14-3-
3 binding.48
Indeed, co-expression with PKA yielded a heavily
phosphorylated SARS-CoV-2 N (Figure 2(C))
containing more than 20 phosphosites according
to LC-MS and MALDI analysis (Supplementary
table 1 and Supplementary data file 1). Especially
dense phosphorylation occurred within the SR-rich
region, involving recently reported in vivo sites
Ser180, Ser194, Ser197, Thr198, Ser201, Ser202
and Thr20513,35 (Figure 2(B) and (D) and Supple-
mentary data file 1), implicating the success of the
PKA co-expression at emulating native phosphory-
lation. Interestingly, due to the frequent occurrence
of Arg residues, it was possible to characterize the
polyphosphorylation of the SR-rich region only with
the use of an alternative protease such as chy-
motrypsin, in addition to datasets obtained sepa-
rately with trypsin (4 independent experiments
overall, see Supplementary data file 1). Due to high
conservation between SARS-CoV and SARS-CoV-
2 N proteins, many phosphosites identified in the
PKA-co-expressed N are likely shared by SARS-
CoV N (Figure 2(B)). Importantly, many identified
phosphosites lie within the regions predicted to be
disordered (Figure 2(A)), and contribute to pre-
dicted 14-3-3-binding motifs, albeit deviating from
the optimal 14-3-3-binding sequence RXX(pS/pT)
X(P/G)44 (Figure 2(B) and Supplementary table 1).
Of note, the bacterially expressed SARS-CoV-
2 N protein avidly binds random E. coli nucleic
acid, which results in a high 260/280 nm
absorbance ratio in the eluate from the nickel-
affinity chromatography column. This is
unchanged by polyphosphorylation (Figure 2(E))
and nucleic acid remained bound even after
further purification using heparin chromatography
(data not shown). To quantitatively remove nucleic
acid from N preparations, we used continuous on-
column washing of the His-tagged protein with
3 M salt. This yielded clean protein preparations
with the 260/280 nm absorbance ratio of 0.6
(Figure 2(E)) of the unphosphorylated and
polyphosphorylated N (pN) with high
electrophoretic homogeneity (Figure 2(F)),
enabling thorough investigation of the 14-3-3
binding mechanism.
SEC-MALS suggested that the nucleic acid-free
protein was a ~95 kDa dimer (Figure 2(F)), based
on the calculated Mw of the His-tagged N
monomer of 48 kDa, regardless of its
phosphorylation status. A significant
overestimation of the apparent Mw of pN from
column calibration, ~160 kDa for the 95 kDa
dimeric species, indicates presence of elements
with expanded loose conformation, in agreement
with the presence of unstructured regions. This
necessitates the use of SEC-MALS for absolute
Mw determination that is independent of the
assumptions on density and shape.
The skewedMw distribution across the SEC peak
indicated the propensity of the SARS-CoV-2 N to
oligomerization (Figure 2(F)), which was instigated
by the addition of nucleic acid (Supplementary
Figure 1(A) and (B)). Using tRNA isolated from
E. coli DH5ɑ cells, SEC and agarose gel
electrophoresis, we showed that our nucleic acid-
free, polyphosphorylated N preparation is capable
of avid binding of noncognate nucleic acid
(Supplementary Figure 1(A)–(C)).
Polyphosphorylated SARS-CoV-2 N and
human 14-3-3c form a tight complex with
defined stoichiometry
Next, we compared the ability of native full-length
SARS-CoV-2 N, both unphosphorylated and
polyphosphorylated (N.1-419 and pN.1-419,
respectively), to be recognized by a human 14-3-3
protein. For the initial analysis we chose 14-3-3c
as one of the strongest phosphopeptide binders
among the 14-3-3 family.55
SEC-MALS (Figure 3(A)) shows that 14-3-3c
elutes as a dimer with Mw of ~55.2 kDa
(calculated monomer Mw 28.3 kDa, see also
Figure 3(B)). The position and amplitude of this
peak did not change in the presence of the N.1-
419 dimer with Mw of 94.5 kDa (calculated
monomer Mw 48 kDa), where the SEC profile
shows two distinct peaks. This is corroborated by
SDS-PAGE analysis of the fractions, suggesting
no interaction between unphosphorylated N
(pI > 10) and 14-3-3 (pI ~ 4.5) despite the large
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difference in their pI values (Figure 3(C) and (D)).
Thus, the presence of 200 mM NaCl was
sufficient to prevent nonspecific interactions
between the two proteins.
In sharp contrast, co-expression of SARS-CoV-
2 N with PKA, and subsequent
polyphosphorylation (Figure 2), allows for tight
complex formation between pN.1-419 and human
14-3-3c. This is evident from the peak shift and
corresponding increased Mw from ~95 to
150.7 kDa (Figure 3(E)), perfectly matching the
addition of the 14-3-3 dimer mass (calculated
dimer Mw 56.6 kDa) to the pN.1-419 dimer
(calculated dimer Mw 96 kDa). The presence of
both proteins in the complex was confirmed by
SDS-PAGE (Figure 3(F)). Collectively these data
pointed toward the equimolar binding upon
saturation. Given the dimeric state of both proteins
in their individual states (Figures 2(F) and 3) and
the Mw of the 14-3-3c/pN.1-419 complex, the
most likely stoichiometry is 2:2. The ratio of the
proteins does not change across the peak of the
complex (Figure 3(F)), implying that they form a
relatively stable complex with the well-defined
stoichiometry.
SARS-CoV-2 N interacts with all human 14-3-3
isoforms
We then questioned whether the interaction with
pN is preserved for other human 14-3-3 isoforms.
Analytical SEC clearly showed that the
phosphorylated SARS-CoV-2 N can be
recognized by all seven human 14-3-3 isoforms,
regardless of the presence of a His-tag or
disordered C-terminal tails on the corresponding
14-3-3 constructs (Figure 4(A)). However, the
efficiency of complex formation differed for each
isoform. Judging by the repartition of 14-3-3
between free and the pN-bound peaks, the
apparent efficiency of pN binding was higher for
14-3-3c, 14-3-3g, 14-3-3f and 14-3-3e, and much
lower for 14-3-3b, 14-3-3s and 14-3-3r, in a
roughly descending order (Figure 4(A)). The
interaction also appeared dependent on the
oligomeric state of 14-3-3, since the monomeric
mutant form of 14-3-3f, 14-3-3fm-S58E56 (appar-
ent Mw 29 kDa) showed virtually no interaction rel-
ative to the wild-type dimeric 14-3-3f counterpart
(apparent Mw 58 kDa), (Figure 4(B)).
Figure 3. Interaction of SARS-CoV-2 N with human 14-3-3c. Interaction between SARS-CoV-2 N protein (50 lM)
and human 14-3-3c (160 lM) was analyzed by SEC-MALS and SDS-PAGE of the eluted fractions. SEC-MALS/SDS-
PAGE of 14-3-3c alone (A,B), with unphosphorylated N (C,D) and with phosphorylated N (E,F) are presented. Mw
distributions obtained using MALS are shown on each peak. “L” shows contents of the samples loaded on a column,
elution volumes corresponding to the maxima of the peaks are indicated by arrows below the gels. Mw markers are
shown to the left of each gel. A black bar on panel F indicates the fractions of the complex between 14-3-3c and pN. A
Superdex 200 Increase 10/300 column equilibrated with 20 mM Tris-HCl buffer pH 7.6 containing 200 mM NaCl and
3 mM NaN3 was operated at a flow rate of 0.8 ml/min. The experiment was performed three times and the most typical
results are shown.
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This apparent variation in binding efficiency
(Figure 4(A)) justified more detailed assessment
of the binding parameters between pN.1-419 and
selected 14-3-3 isoforms.
Affinity of the phosphorylated SARS-CoV-2 N
towards selected human 14-3-3 isoforms
In light of the relative positions of the two proteins,
separately and complexed, on SEC profiles
Figure 4. SARS-CoV-2 N interacts with all seven dimeric human 14-3-3 isoforms, but not with the monomeric
mutant of 14-3-3f. A. Interaction between phosphorylated N protein (46.6 lM) and human isoforms 14-3-3c (69.4 lM),
his-tagged 14-3-3cDC (73.9 lM), his-tagged 14-3-3gDC (73.8 lM), 14-3-3f (77.6 lM), his-tagged 14-3-3e (76.2 lM),
14-3-3eDC (60.3 lM), 14-3-3bDC (69.4 lM), 14-3-3sDC (71.7 lM), 14-3-3rDC (75.4 lM) studied by analytical SEC on
a Superdex 200 Increase 5/150 column at 200 mM NaCl. B. Phosphorylated N protein (46.6 lM) interacts with the
wild-type dimeric 14-3-3f (77.6 lM) but not with its monomeric mutant 14-3-3fm-S58E (74.9 lM). Apparent Mw
indicated in kDa were determined from column calibration.
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(Figures 3 and 4), we used analytical SEC to track
titration of a fixed concentration of pN.1-419
(around 10 lM) against increasing quantities (0–
100 lM) of either of two selected full-length
human 14-3-3 isoforms, c and e (Figure 5(A) and
(B)). A saturation binding curve showed the
maximal concentration of bound 14-3-3c to
asymptotically approach 10 lM (Figure 5(C)),
supporting 2:2 stoichiometry. The apparent KD of
the 14-3-3c/pN.1-419 complex was estimated as
1.5 ± 0.3 lM. A similar binding mechanism could
be observed for 14-3-3e, however in this case we
could achieve pN.1-419 saturation only at much
higher 14-3-3e concentrations (Figure 5(B) and
(C)), and the resulting apparent KD was ~7 times
higher than for 14-3-3c (Figure 5(C)).
Nevertheless, once again the stoichiometry was
close to 2:2. These findings strongly disfavor the
earlier hypothesis that 14-3-3 binding affects
dimerization status of N.57
We further asked what are the specific regions of
SARS-CoV-2 N that are responsible for interaction
with human 14-3-3.
The N-terminal part of SARS-CoV-2 N is
responsible for 14-3-3 binding
Among multiple phosphosites identified in our
pN.1-419 preparations (Supplementary table 1),
the two most interesting regions are located in the
intrinsically disordered or loop segments (Figure 2
(A)), normally favored by 14-3-3 proteins.45 The first
represents the C-terminally located RTA[pT265]KAY
site, which is predicted by the 14-3-3-Pred web-
server58 as the 14-3-3-binding site within the loop
region immediately preceding the CTD. The sec-
ond, SR-rich region features multiple experimen-
tally confirmed phosphosites including several
suboptimal predicted 14-3-3-binding sites (Figure 2
(B)). To narrow down the 14-3-3-binding locus we
used several constructs representing its N- and C-
terminal parts (N.1-211 and N.212-419, respec-
tively). The individual CTD included the C-terminal
phosphosite around Thr265 (N.247-364), and the
longer N-terminal construct extended toward the
C-terminus to include the predicted NES sequence
(N.1-238) (Figure 6(A)). This contains Asp225 and
a cluster of Leu residues which together resemble
the unphosphorylated 14-3-3-binding segments
from ExoS/T59 and therefore could be important
for 14-3-3 binding.
As for the wild-type protein, the truncated SARS-
CoV-2 N constructs were cloned and expressed in
the absence or presence of PKA to produce
unphosphorylated or polyphosphorylated proteins.
PKA could be easily detected in the eluate from
the Ni-affinity column and typically led to an
upward shift on SDS-PAGE and a shift on the
SEC profile (Supplementary Figure 2). Each
indicates efficient phosphorylation. Perhaps with
the exception of N.212-419, phosphorylation did
not affect the oligomeric state of the N constructs,
and the observed shifts could be accounted for by
the affected flexible regions (Figure 4 and
Supplementary Figure 2).
SEC-MALS (Supplementary Figure 2) indicates
the N.247-364 construct (calculated monomer Mw
15.3 kDa), previously crystallized and kindly
provided by Prof. Baumeister’s laboratory, exists
as a ~30 kDa dimer. This is in perfect agreement
Figure 5. Binding affinity. pN at a fixed concentration (~10 lM) was titrated against either of the two human 14-3-3
isoforms and monitored by analytical SEC with serial sample loading. A. Titration of pN with 14-3-3c. B. Titration of pN
with 14-3-3e. Changes of the elution profiles associated with the increasing 14-3-3 concentration are shown by
arrows. C. Binding curves used for apparent KD determination. Note that, regardless of the observed differences in
the affinities, the maximum 14-3-3 concentration complexed with pN equals the concentration of pN (~10 lM) for both
14-3-3 isoforms. Typical results from two independent experiments are shown.
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with earlier published data.28 A dimeric state (Mw of
47.3 kDa) was also confirmed for the longer C-
terminal construct, N.212-419 (Supplementary Fig-
ure 3, calculatedmonomer Mw 23.3 kDa), however,
in this case a skewed Mw distribution indicative of
the polydispersity and tendency for oligomerization
was observed (Supplementary Figure 3).
In contrast, N-terminal constructs including the
RNA-binding domain, such as N.1-211, are
monomeric (Supplementary Figure 3). Thus, our
data align with the low-resolution structural model
of SARS-CoV and SARS-CoV-2 N proteins, in
which the CTD (residues 247-364), largely
responsible for dimerization, and NTD, involved in
RNA-binding, are only loosely associated.24,28,29
Of the constructs analyzed, the N-terminal
constructs N.1-211 and N.1-238 both interacted
with 14-3-3c by forming distinct complexes on
SEC profiles, and this interaction was strictly
phosphorylation-dependent (Figure 6). Given the
similarity of the elution profiles for pN.1-211 and
pN.1-238, it may be concluded that the presence
of NES in the latter is dispensable for the 14-3-3
binding.
Under similar conditions, only a very weak
interaction between the dimeric pN.212-419
construct and 14-3-3c could be observed,
whereas the phosphorylated dimeric CTD
(pN.247-364) displayed virtually no binding
(Figure 6). Neither unphosphorylated construct
interacted with 14-3-3. Thus, the Thr265
phosphosite can be broadly excluded as the
critical binding site. Separate phosphosites
outside the CTD, for instance, in the last ~30 C-
terminal residues (Supplementary table 1) likely
account for residual binding of the pN.212-419
construct. Only its SEC profile showed a
significant positional peak shift with
phosphorylation (Figure 6(B) and (C)), indicating a
potential change in the oligomeric state. It is
tempting to speculate that such phosphorylation
outside the CTD could affect higher order
oligomerization associated with the so-called N3
C-terminal segment (Figure 2(B)).20,21,49,60
Figure 6. Interaction of human 14-3-3c with individual SARS-CoV-2 N protein domains. A. Schematic represen-
tation of the N protein sequence with the main domains/regions highlighted. Yellow indicates NES, small red circles
designate phosphosites within the two corresponding phosphorylatable loci. B. SEC profiles of individual 14-3-3c
(black traces), individual N (red traces), and 14-3-3 with N (blue traces) obtained using a Superdex 200 Increase 5/
150 column at 200 mM NaCl in running buffer and operated at a 0.45 ml/min flow rate. The upper row corresponds to
unphosphorylated N fragments, the bottom row corresponds to their phosphorylated counterparts, as indicated on
each panel. In all cases, 50 lM of N was mixed with 50 lM of 14-3-3 and loaded in an equal volume of 50 ll. In the
case of N.247-364 and pN.247-364, 90 lM of N was used. Note that the well-defined complexes with 14-3-3 were
observed only for pN.1-211 and pN.1-238 fragments. The experiment was repeated twice and the most typical results
are presented.
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According to SEC-MALS, the 14-3-3c dimer (Mw
57 kDa) interacts with the pN.1-238 monomer (Mw
of 31 kDa) by forming a ~82 kDa complex
(Figure 7(A)) with an apparent 2:1 stoichiometry. It
is remarkable that despite a moderate molar
excess of pN.1-238 a 2:2 complex (one 14-3-3
dimer with two pN monomers) is not observed.
The well-defined 2:2 stoichiometry of the 14-3-3c
complex with the full-length pN (Figure 3)
suggests that the dimeric pN is anchored using
two equivalent, key 14-3-3-binding sites, each
located in a separate subunit of N. It is tempting to
speculate that, in the absence of the second
subunit, the interaction involves the key
phosphosite and an additional phosphosite which
is separated by a sufficiently long linker (15
residues),61 to secure occupation of both
phosphopeptide-binding groovesof 14-3-3 (Figure 7
(B)). Such bidentate binding would prevent the
recruitment of a second pN.1-238 monomer and is
in line with the observed data. Similar 2:1 binding
was observed qualitatively for the interaction of
14-3-3c with pN.1-211 (Figure 6(C) and data not
shown).
Our finding that the minimal N-terminal construct
pN.1-211 exhibits firm binding to 14-3-3c indicates
that the key 14-3-3-binding phosphosite(s) is/are
located exclusively within this region. Given the
presence of numerous candidate 14-3-3-binding
sites within its most C-terminal part, i.e., the SR-
rich region, we further focused on the 1-211
sequence in search of the 14-3-3-binding
phosphosite(s).
Localization of the main 14-3-3-binding site
within the SR-rich region of SARS-CoV-2 N
Further N mutants were designed to disrupt the
most probable 14-3-3-binding phosphosites.
These are located in the intrinsically flexible
phosphorylatable SR-rich segment centered at
positions 197 and 205 (Figure 8(A)). Both
represent suboptimal 14-3-3-binding motifs SRN
[pS197]TP and SRG[pT205]SP in lacking an Arg/
Lys residue in position 3 (bold font) relative to
the phosphorylation site (squared brackets).
However, each also features a Pro residue in
position + 2 (bold underlined font), which is highly
favorable for 14-3-3 binding44 and absent from the
other potential 14-3-3-binding phosphosites found
in the SR-rich region (Figure 2(B)). These conflict-
ing factors complicate predictions for the true 14-
3-3-binding site. Moreover, even beyond the SR-
rich region the NTD is predicted to host further pos-
sible 14-3-3-binding phosphosites, including the
RRA[pT91]RR site, which is the highest-scoring in
14-3-3-Pred58 prediction (Supplementary table 1).
We conceived stepwise truncations to remove the
most probable 14-3-3-binding phosphosites, aiming
to identify the iteration at which binding (observed
for the pN.1-211 construct) ceased. 14-3-3 can
bind incomplete consensus motifs at the extreme
C-terminus of some proteins,62 so truncations were
designed to remove the critical phosphorylated resi-
due. However, upstream residues of each candi-
date 14-3-3-binding site were preserved, in light of
the sheer number of overlapping potential binding
motifs in the SR-rich region (Figure 8(A)).
The new truncated constructs of N, namely N.1-
204, N.1-196 and N.1-179, were obtained in
unphosphorylated and phosphorylated states, as
before, and again washed with high salt to remove
potentially disruptive nucleic acid. SEC-MALS
confirmed the monomeric state of the N-terminal
N mutants (the exemplary data are presented for
N.1-196, Supplementary Figure 3), consistent with
the proposed architecture of the N protein.21,24
None of the truncated mutants interacted with 14-
3-3c in the unphosphorylated state (Figure 8(B)).
More importantly, no binding to 14-3-3c was
Figure 7. Interaction of human 14-3-3c with the phosphorylated monomeric SARS-CoV-2 N construct 1–238. A.
SEC-MALS analysis of individual pN, 14-3-3c and their complex formed at the indicated molar excess of pN. Protein
concentration, MALS-derived Mw distributions across the peaks and the respective average Mw values are indicated.
Note that the difference shown by a two-headed arrow roughly corresponds to a pN.1-238 monomer mass. B.
Schematic representation of the possible bidentate binding mode where the 14-3-3 dimer interacts with the tentative
key 14-3-3-binding phosphosite and another sterically allowed phosphosite separated by a sufficiently long linker.
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detected with phosphorylated N.1-179 (Figure 8(C))
and only very limited binding could be observedwith
phosphorylatedN.1-196 (Figure 8(C)). This strongly
indicated that all phosphosites of the 1-196
segment (including at least three phosphosites
within the SR-rich region, i.e., Ser180, Ser188 and
Ser194, see Figure 8(A)) are dispensable for 14-
3-3 binding and at most could contribute only as
auxiliary sites (as suggested by the scheme in
Figure 7(B)). This narrowed the 14-3-3-binding
region within SARS-CoV-2 N down to 15 residues
from 196 to 211, leaving only two possible sites
centered at Ser197 and Thr205 (Figure 8(A)).
By contrast, pN.1-204 showed only a very slightly
altered interaction with 14-3-3c compared to pN.1-
211 (Figure 8(C)). Although this does not exclude
that Thr205 phosphosite may contribute to 14-3-3
binding in the context of the full-length pN
(particularly if pSer197 is absent or mutated),
pSer197 appears to be critical for 14-3-3
recruitment. Intriguingly, in contrast to Thr205,
Ser197 is preserved in most related coronavirus N
proteins (see Figures 2(B) and 9).
Discussion
In this work, we investigated the molecular
association between the SARS-CoV-2 N protein
and human phosphopeptide-binding proteins of
the 14-3-3 family. The former is the most
abundant viral protein,12,13 the latter is a major pro-
tein–protein interaction hub involved in multiple cel-
lular signaling cascades, expressed at high levels in
many human tissues including those susceptible to
SARS-CoV-2 infection (Figure 1).40 SARS-CoV-2 N
is heavily phosphorylated in infected cells,13,35,36
which poses a significant challenge for proteomic
approaches: the densely phosphorylated SR-rich
region alone, functionally implicated in numerous
viral processes,34,49,63 hosts seven closely spaced
Arg residues (Figure 2(B)). These arginines restrict
the length of tryptic phosphopeptides and decrease
Figure 8. Localization of the 14-3-3-binding sites within the SR-rich region of the SARS-CoV-2 N protein. A.
Sequence of the SR-rich region showing potential 14-3-3-binding sites (around residues 180, 188, 194, 197 and
205) and the truncations designed to exclude Thr205, or Thr205 and Ser197 (blue font), or Thr205, Ser197 and other
candidate 14-3-3-binding phosphosites (green font). # denotes the designed C-terminus. B, C. Analysis by SEC of the
interaction between human 14-3-3c and the truncated mutants of SARS-CoV-2 N in their unphosphorylated (B) or
phosphorylated forms (C). Each graph contains SEC profiles for the individual 14-3-3 (black line), individual N or pN
construct (red line), and the 14-3-3c + N (or pN) mixture (blue line) where 50 lM of each protein was used throughout.
Inserts on panel C show the upward shift on SDS-PAGE as the result of phosphorylation (U, unphosphorylated; P,
phosphorylated protein, arrowheads indicate the shift). Note that only the phosphorylated mutants interacted with 14-
3-3c and that only pN.1-211 and pN.1-204 formed a defined complex with 14-3-3c. Column: Superdex 200 Increase 5/
150, flow rate: 0.45 ml/min. The experiment was repeated twice and the most typical results are presented.
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the probability of their unambiguous identification
and phosphosite assignment.64 The multiplicity of
implicated protein kinases (including GSK-3, pro-
tein kinase C, casein kinase II and mitogen-
activated protein kinase36,37,50) further hinders
study of specific phosphorylations. Assuming that
the mechanistic implication of a specific phosphory-
lation is independent of the acting kinase, we pro-
duced polyphosphorylated N protein (pN) via
bacterial co-expression with a catalytic subunit of
PKA. A combination of orthogonal cleavage
enzymes and LC-MS phosphoproteomics
mapped > 20 phosphosites (Supplementary table
1) including Ser23, Thr24, Ser180, Ser194,
Ser197, Thr198, Ser201, Ser202, Thr205 and
Thr391 reported recently at SARS-CoV-2 infec-
tion.13,35 At least six of the identified phosphosites
are located in the unstructured regions and repre-
sent potential 14-3-3-binding sites (Figure 2(A)
and (B)).
Biochemical analysis confirmed that
polyphosphorylated N is competent for binding to
all seven human 14-3-3 isoforms (Figures 3 and
4), but revealed remarkable variation in binding
efficiency between them (Figure 4). This was
supported by the quantified affinities to two
selected isoforms, 14-3-3c (KD of 1.5 mM) and 14-
3-3e (KD of 10.7 mM) (Figure 5). Our observations
are in line with the recent finding that 14-3-3c and
14-3-3g systematically bind phosphopeptides with
higher affinities than 14-3-3e and 14-3-3r.55 The
low micromolar-range KD values compare well to
those reported for other physiologically relevant
partners of 14-3-3,65–67 indicating a stable and
specific interaction. Meanwhile, the well-defined
2:2 stoichiometry of the ~150-kDa 14-3-3/pN com-
plex, supported by titration experiments and SEC-
MALS analysis (Figures 3 and 5), excludes the pos-
sibility that 14-3-3 binding disrupts pN dimeriza-
tion.57 It is reasonable to assume that the
principally bivalent 14-3-3 dimer44,46 recognizes just
one phosphosite in each pN subunit because a
bidentate 14-3-3 binding to different phosphosites
within a single pN subunit would inevitably alter
Figure 9. Association of SARS-CoV-2 N with human 14-3-3. A. A topology model for the complex of SARS-CoV-2 N
protein dimer with the dimer of human 14-3-3 illustrating the occlusion of the SR-rich region. Although pSer197 is
critical for the 14-3-3 binding, other phosphosites (e.g., the semiconserved Thr205) may play a secondary role. B.
Local alignment of SR-rich regions of the most similar coronavirus N proteins in order of descending sequence identity
(s.id.) determined using entire N protein sequences. Alignment was performed using Clustal omega and visualized
using Mview (https://www.ebi.ac.uk/Tools/msa/mview/) with the following coloring scheme. Residues identical to
those in the SARS-CoV-2 sequence are shadowed by grey, phosphorylatable residues in positions 197 and 205 are in
green color, residues blocking phosphorylation in position 205 are in red.
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the observed 2:2 stoichiometry. Identification of the
single phosphosite responsible for 14-3-3 recruit-
ment proved challenging, as none of the potential
sites were a perfect match to the currently known
optimal 14-3-3-binding motifs.65
To restrict the search, we analyzed the interaction
of various N constructs with 14-3-3c. This
eliminated the high-scoring potential 14-3-3-
binding phosphosite RTApT265KAY, present in the
C-terminal N fragments, as the true site of
interaction despite its conservation in many
related coronavirus N proteins (Supplementary
table 2 and 3). The residual binding of pN.212-419
to 14-3-3c suggested the existence of auxiliary 14-
3-3-binding sites located outside the folded CTD
(residues 247–364). Both pN.1-211 and pN.1-238
bound 14-3-3 with comparable efficiency
suggesting the binding lies between amino acid 1
and 211. Interestingly, the N-terminal constructs
existed as monomers (Supplementary Figure 3),
which could potentially lower the binding affinity to
14-3-3 dimers in light of the 2:2 stoichiometry.
Nonetheless, sufficient phosphorylation-dependent
binding was clearly observed between the dimeric
14-3-3c and the monomeric N-terminal constructs
(Figures 6 and 7).
Truncation of the SR-rich region streamlined the
search for the 14-3-3-binding site to the 15-
residue stretch of amino acids 196–211. This
sequence hosts two principally similar potential
14-3-3-binding sites, RNpS197TP and RGpT205SP
(Figure 2(B) and (D)). Importantly, the proximity of
these sites rules out their simultaneous bidentate
binding to the 14-3-3 dimer: 14-3-3 binds in an
antiparallel manner requiring a minimum of 13–15
residues between phosphosites on a single
peptide.44,68 Thus, binding to Ser197 and Thr205
sites must be mutually exclusive.
Themarkedly different binding between pN.1-204
and pN.1-196 to 14-3-3 (Figure 8) prompted us to
propose Ser197 as the critical phosphosite. This
finding aided the design of a topology model for
the complex (Figure 9(A)), in which the 14-3-3
dimer is anchored by two identical Ser197
phosphosites from the SR-rich region in the two
equivalent pN chains. Noteworthily, the RN(pS/
pT)197TP site is conserved in not only SARS-CoV
and SARS-CoV-2 but also in N proteins from
several bat and pangolin coronaviruses (Figure 9
(B)). Meanwhile, plausible phosphorylation of
residue 205 is possible in a smaller subset of
coronaviruses (Figure 9(B)).
The model shown in Figure 9(A) notably does not
exclude the possibility of 14-3-3 binding to
alternative phosphosites under significantly
different phosphorylation conditions. Moreover, we
speculate that hierarchical phosphorylation within
the SR-rich region36 would alter 14-3-3 binding with
phosphorylation at adjacent Ser/Thr residues, likely
to inhibit the interaction.69 The SR-rich region is
phosphorylated by both Pro-directed and non-Pro-
directed protein kinases.36,37,39,50 Since 14-3-3 pro-
teins typically reject peptides with a proline adjacent
to the phosphorylated residue, the interplay
between these aforementioned kinases could be
regulatory. In theory, this could create a phosphory-
lation code and conditional binding of 14-3-3, as has
been discussed recently for alternative polyphos-
phorylated 14-3-3 partners such as LRRK2, CFTR
and tau protein.48,67,70,71
The recruitment of the 14-3-3 dimer is expected to
occlude the SR-rich region of N by masking 10–20
residues surrounding the Ser197 phosphosite
within the complex. Apart from the likely effects on
the properties of N and its ability to phase
separate and bind RNA, the 14-3-3 binding at the
SR-rich region, triggered by phosphorylation, can
potentially interfere with N binding to the M
protein, an event clearly relevant to the virion
assembly.17 In support of this hypothesis, the 14-
3-3-occluded area reported here overlaps with the
N region (residues 168–208) proposed to mediate
its association with the M protein in SARS-CoV.19
The presence of SR-rich regions in many viral N
proteins suggests a more broad interaction of 14-
3-3 with N proteins. Indeed, using 14-3-3-Pred
prediction58 a number of 14-3-3-binding phospho-
sites in N proteins from human (Supplementary
table 2) and bat coronaviruses (Supplementary
table 3) could be identified. Some display strong
conservation of the 14-3-3-binding site around
Ser197 (Figure 9(B)), whereas others contain sepa-
rate high-scoring potential 14-3-3-binding sites
beyond the SR-rich region. Given the reasonable
threat that other zoonotic coronaviruses may ulti-
mately enter the human population,72,73 the rele-
vant N proteins are highly likely to undergo
phosphorylation and 14-3-3 binding, as seen for
SARS-CoV-2 N. This is particularly likely, given
the high concentration of both proteins in the
infected cells (see above).
Our findings underline the essential role of the
SR-rich region in the biology of N proteins and
host-virus interactions.49 Unrelated proteins with
similar domains also tend to show RNA-binding
capability (e.g., the splicing factors)74,75 and are
subject to multisite phosphorylation.76 Such pro-
teins are often associated with phase separation
as a means to regulate membraneless compart-
mentalization within the cytoplasm. Likewise,
SARS-CoV-2 N protein has been shown to undergo
phase separation in vitro upon RNA addition: a phe-
nomenon dependent on the concentration of salt,
presence of divalent ions, phosphorylation state of
N and on RNA sequence.30,34,77,78 Furthermore,
the N protein has been shown to recruit the RNA-
dependent RNA-polymerase complex, and
granule-associated heterogeneous nuclear ribonu-
cleoproteins forming phase separated granules
which can aid SARS-CoV-2 replication.30,34 Thus
14-3-3 potentially influences phase separation by
binding the SR-rich region and may also affect the
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accessibility of the NES sequence located nearby
(Figure 2(B)). This in turn may impact nucleocyto-
plasmic shuttling of N, as seen for SARS-CoV N.37
Conclusively, 14-3-3 binding to the SR-rich region
of N holds potential to regulate multiple host cell
processes affected by N. 14-3-3 binding to pN
may present a cell immune-like response to the
viral infection aimed at arresting or neutralizing N
activities.57 On the other hand, in light of the abun-
dance of N protein in the infected cell,12,13 pN may
instead arrest 14-3-3 proteins in the cytoplasm
and indirectly disrupt cellular processes involving
14-3-3. For example, 14-3-3e and 14-3-3g each
play a role in the innate immune response via
RIG-1 and MDA5 signaling, respectively.79,80 The
N protein:14-3-3 interaction would modulate these
and other signaling pathways involving 14-3-3 pro-
teins. Intriguingly, two 14-3-3 isoforms, f and e,
have been detected in purified particles of infectious
bronchitis coronavirus.81 The 14-3-3 protein take up
could be mediated by its interaction with N, poten-
tially resulting in the 14-3-3 transmission between
coronavirus hosts.
As such, understanding the molecular
mechanism of pN association with 14-3-3 proteins
may inform the development of novel therapeutic
approaches and paves the road for structural
studies.
Materials and Methods
Protein expression and purification
The tagless SARS-CoV-2 N gene coding for
Uniprot ID P0DTC9 protein sequence was
commercially synthesized (GeneWiz) and cloned
into pET-SUMO bacterial expression vectors
using NdeI and HindIII restriction endonuclease
sites. To obtain constructs of N carrying the N-
terminal His6-tag cleavable by HRV-3C protease
(N.1-419, N.1-211, N.1-238, N.212-419), the N
gene was PCR amplified using primers listed in
Supplementary table 4 and cloned into the pET-
YSBL-Lic-3C plasmid vector using an established
ligation-independent cloning procedure.82 After 3C
cleavage each construct contained extra GPA resi-
dues at the N terminus. The N.247-364 construct
carrying an N-terminal uncleavable His6-tag and
corresponding to the previously crystallized folded
CTD dimer,28 was kindly provided by Prof. W.
Baumeister’s laboratory.
Truncated mutants of N.1-211, namely N.1-179,
N.1-196 and N.1-204 were derived from the wild-
type N plasmid using the standard T7 forward
primer with varying reverse primers listed in
Supplementary table 4. Each carried a BamHI site
to enable consequent cloning into a pET28 vector
using NcoI and BamHI sites. This preserved the
N-terminal His6-tag cleavable by 3C protease. All
constructs were validated by DNA sequencing.
Untagged full-length human 14-3-3c (Uniprot ID
P61981) and 14-3-3f (Uniprot ID P63104) cloned
in a pET21 vector, and full-length human 14-3-3e
(Uniprot ID P62258) carrying an N-terminal His6-
tag cleavable by Tobacco Etch Virus (TEV)
protease, and cloned into a pRSET-A vector have
been previously described.83–85 Truncated versions
of human 14-3-3g (Uniprot ID Q04917), 14-3-3b
(Uniprot ID P31946), 14-3-3e (Uniprot ID P62258),
14-3-3s (Uniprot ID P27348), 14-3-3c (Uniprot ID
P61981) and 14-3-3r (Uniprot ID P31947) devoid
of the short disordered segment at the C terminus,
cloned into pProExHtb vector and carrying TEV-
cleavable His6-tags on their N-terminal ends were
obtained as described previously.66,86 The mono-
meric mutant form of untagged full-length human
14-3-3f carryingmonomerizing amino acid substitu-
tions and pseudophosphorylation in the subunit
interface (14-3-3fm-S58E) was obtained as
before.56
14-3-3c, 14-3-3f and 14-3-3fm-S58E were
expressed and purified using ammonium sulfate
fractionation and column chromatography as
previously described.83 His6-tagged N.247-364
was also expressed and purified as before.28 All
other proteins carrying cleavable His6-tags were
expressed in E. coli BL21(DE3) cells and purified
using subtractive immobilized metal-affinity chro-
matography (IMAC) and gel-filtration. For the N pro-
tein and its various constructs the eluate from the
first IMAC column, performed at 1 M NaCl, har-
bored a significant quantity of random bound
nucleic acid (the 260/280 nm absorbance ratio of
1.7–2.0). This necessitated an additional long on-
column washing step with 3 M NaCl (50 column vol-
umes) to ensure the 260/280 nm absorbance ratio
of ~0.6 and removal of all nucleic acid. Tagless N
protein was purified after treatment of cell lysate
with RNAse, using heparin and subsequent ion-
exchange chromatography on a sulfopropyl
Sepharose (elution gradients 100–1000 mM NaCl)
followed by gel-filtration. Here, it proved challenging
to entirely eliminate nucleic acid and the typical
260/280 nm absorbance ratio was 0.7–0.9.
Protein concentration was determined by
spectrophotometry at 280 nm on a N80
Nanophotometer (Implen, Munich, Germany)
using sequence-specific extinction coefficients
calculated using the ProtParam tool in ExPASy
(see Supplementary table 5).
Isolation of E. coli tRNA
The DH5ɑ cells were incubated in 30 ml of liquid
medium (LB without antibiotics) for 16 h at 37 C
with maximum aeration and then harvested by
centrifugation at 7000g for 10 min. The pellet was
gently resuspended in RNAse-free Tris-acetate
buffer, followed by alkali-SDS lysis and
neutralization by cold ammonium acetate. The
suspension was incubated on ice for 5 min and
centrifuged at 21,000g for 10 min at 4 C. The
resulting supernatant (8 ml) was incubated with
12.5 ml isopropanol for 15 min at 25 C and
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centrifuged at 12,100g for 5 min. The pellet was
resuspended in 800 ml of 2 M ammonium acetate,
incubated for 5 min at 25 C and centrifuged
(12,100g, 10 min). RNA was precipitated from
supernatant by 800 ml of isopropanol, incubated
for 5 min at 25 C and centrifuged (12,100g,
5 min). After supernatant removal the pellet was
washed with 70% ice-cold ethanol, dried and
dissolved in 100–200 ml milliQ-water.
SARS-CoV-2 N protein co-expression with PKA
For phosphorylation in cells, SARS-CoV-2 N was
bacterially co-expressed with a catalytic subunit of
mouse protein kinase A (PKA), as described
previously.48 PKA was cloned into a low-copy
pACYC vector48 which ensured that the target pro-
tein was expressed in excess over kinase.
PKA and SARS-CoV-2 N were co-transformed
into E. coli BL21(DE3) cells against
Chloramphenicol and Kanamycin resistance,
respectively. Cells were grown in LB to an OD600
reading of 0.6 before inducing with 1 mM of IPTG.
After induction, cultivation was continued for 1.5 h,
3 h, 4 h and overnight at 37 C, and 4 h was
found to be sufficient to provide for the saturating
interaction with 14-3-3. For all truncated
constructs of N, overnight co-expression was
used. For unphosphorylated controls we
expressed proteins in the absence of PKA.
The cells with overexpressed proteins were
harvested by centrifugation and resuspended in
20 mM Tris-HCl buffer pH 8.0 containing 1 M
NaCl, 10 mM imidazole, 0.01 mM
phenylmethylsulfonyl fluoride, as well RNAse to
reduce the RNA content. Phosphorylated proteins
were purified using subtractive IMAC and gel-
filtration, whereby the His6-tagged PKA was
efficiently removed. Phosphorylated N and its
constructs typically showed significant shifts on
SDS-PAGE and PhosTag gels indicating
phosphorylation.
Identification of phosphosites within N
Sample treatment for proteomics analysis.
For phosphopeptide mapping, the SARS-CoV-2 N
protein co-expressed with PKA for 4 h at 30 C
was purified as above. An aliquot (35 lg) was
subjected to enzymatic hydrolysis “in solution”
either with trypsin (Sequencing Grade Modified
Trypsin, Promega) or with chymotrypsin
(Analytical Grade, Sigma-Aldrich). Briefly, the
sample preparation was as follows. The sample
was reduced with 2 mM Tris(2-carboxyethyl)
phosphine (TCEP) and then alkylated with 4 mM
S-Methyl methanethiosulfonate (MMTS); a
protein:enzyme ratio was kept at 50:1 (w/w);
digestion was performed overnight at 37 C and
pH 7.8 (for chymotrypsin, 10 mM Ca2+ was added
to the reaction solution). The reaction was
stopped by adjusting it to pH 2 with formic acid.
The resulting peptides were purified on a custom
micro-tip SPE column with Oasis HLB (Waters) as
a stationary phase, using elution with an
acetonitrile:water:formic acid mix (50:49.9:0.1 v/v/
v%). The eluate of resulting peptides was dried
out and stored at 30 C prior to the LC-MS
experiment.
LC-MS/MS experiment. Peptides were
separated on a nano-flow chromatographic
system with a flow rate of 440 nl/min (Ultimate
3000 Nano RSLC, Thermo Fisher Scientific) and
ESI coupled to a mass-analyzer (Q Exactive Plus,
Thermo Fisher Scientific). Briefly, the protocol was
as follows. Dried peptide samples were rehydrated
with 0.1% formic acid. An aliquot of rehydrated
peptides (5 ll) was injected onto a precolumn
(100 lm  2 cm, Reprosil-Pur C18-AQ 1.9 lm,
Dr. Maisch GmbH) and eluted on a nano-column
(100 lm  30 cm, Reprosil-Pur C18-AQ 1.9 lm,
Dr. Maisch GmbH) with a linear gradient of mobile
phase A (water:formic acid 99.9:0.1 v/v%) with
mobile phase B (acetonitrile:water:formic acid
80:19.9:0.1 v/v/v%) from 2% till 80% B within
80 min. MS data were acquired by a data-
dependent acquisition approach after a MS-scan
of a 350–1500 m/z range. Top 12 peaks were
subjected to high collision energy dissociation
(HCD) or electron transfer dissociation (ETD).
After a round of MS/MS, masses were
dynamically excluded from further analysis for 35 s.
MS data analysis. For Mascot (MatrixScience)
database search, raw LC-MS files were converted
to general mgf format using MSConvert with its
default settings. For peptide database search, a
concatenated database including SARS-CoV-2
and general contaminants was constructed. The
parameters of the search were: Enzyme – Trypsin
with one miscleavage allowed, or in case of
Chymotrypsin - no enzyme; MS tolerance –
5 ppm; MSMS – 0.2 Da; Fixed modifications –
Methylthio(C); Variable modifications – Phospho
(ST), Phospho(Y), Oxidation(M). For PEAKS
(PEAKS Studio Xpro, Bioinformatics Solutions
Inc.) analysis the parameters of a search were MS
tolerance  10 ppm, MSMS – 0.05 Da; Fixed
modifications – Methylthio(C); Variable
modifications – Phospho(STY), Oxidation(M),
Ammonia-loss (N), Deamidation (NQ). For




The oligomeric state of proteins as well as
protein–protein and protein-tRNA interactions
were analyzed by loading 50 ml samples on a
Superdex 200 Increase 5/150 column (GE
Healthcare) operated at a 0.45 ml/min flow rate
using a Varian ProStar 335 system (Varian Inc.,
Melbourne, Australia). When specified, a
Superdex 200 Increase 10/300 column (GE
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Healthcare) operated at a 0.8 ml/min flow rate was
used (100 ml loading). The columns were
equilibrated by a 20 mM Tris-HCl buffer, pH 7.6,
containing 200 mM NaCl and 3 mM NaN3 (SEC
buffer) and calibrated by the following protein
markers: BSA trimer (198 kDa), BSA dimer
(132 kDa), BSA monomer (66 kDa), ovalbumin
(43 kDa), a-lactalbumin (15 kDa). The profiles
were followed by 280 nm and (optionally) at
260 nm absorbance. Diode array detector data
were used to retrieve full-absorbance spectral
information about the eluted samples including
protein and nucleic acid. All SEC experiments
were performed at least three times and the most
typical results are presented.
To assess binding parameters for the 14-3-3/
pN.1-419 interaction, we used serial loading of the
samples containing a fixed pN concentration and
increasing concentrations of 14-3-3 in a constant
volume of 50 ml and a Superdex 200 Increase
5/150 column operated at 0.45 ml/min. To validate
linear augmentation of the peak amplitude with
increasing protein concentration, serial loading of
14-3-3 alone at different concentrations was used.
Such linear dependence allowed conversion of the
amplitude of the 14-3-3 peak into the molar
concentration of its unbound form at each point of
titration. Concentration of pN-bound 14-3-3 was
determined as the difference between the total
and free concentration. Binding curves
representing the dependence of bound 14-3-3 on
its total concentration were approximated using
the quadratic equation to determine apparent KD
values. Graphing and fitting were performed in
Origin 9.0 (OriginLab Corporation, Northampton,
MA, USA).
Size-exclusion chromatography coupled to
multi-angle light scattering (SEC-MALS)
To determine the absolute masses of various N
constructs and their complexes with 14-3-3, we
coupled a SEC column to a ProStar 335 UV/Vis
detector (Varian Inc., Melbourne, Australia) and a
multi-angle laser light scattering detector
miniDAWN (Wyatt Technologies). Either Superdex
200 Increase 10/300 (~24 ml, flow rate 0.8 ml/min)
or Superdex 200 Increase 5/150 (~3 ml, flow rate
0.45 ml/min) columns (GE Healthcare) were used.
The miniDAWN detector was calibrated relative to
the scattering from toluene and, together with
concentration estimates obtained from UV
detector at 280 nm, was exploited for determining
the Mw distribution of the eluted protein species.
All processing was performed in ASTRA 8.0
software (Wyatt Technologies) taking dn/dc equal
to 0.185 and using extinction coefficients listed in
Supplementary table 5. Protein content in the
eluted peaks was additionally analyzed by SDS-
PAGE.
Data availability
The source LC-MS data on SARS-CoV-2 N
phosphoproteomics are available along with the
paper as a Supplementary data file 1.
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